Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Add filters

Year range
Chinese Journal of Rheumatology ; (12): 110-113, 2014.
Article in Chinese | WPRIM | ID: wpr-444305


Objective To evaluate the dosage regimen of sulfasalzine combined with recombinant human tumor necrosis factor receptor-Fc fusion protein (rhTNFR) in the induction and maintenance of remission in active ankylosing spondylitis.Methods This study enrolled 100 ankylosing spondylitis patients with disease duration for less than five years who were treated with sulfasalzine and rhTNFR combination therapy.Patients were randomly assigned to three groups six weeks later:patients in the G1 group received sulfasalzine combined with rhTNFR at a 25 mg dosage twice each week.Patients shifted to monotherapy with sulfasalzine six weeks later:patients in G2 group received sulfasalzine combined with rhTNFR at 25 mg dosage per week.Patients were switched to monotherapy of sulfasalzine twelve weeks later:patients in G3 group received sulfasalzine combined with rhTNFR at 25 mg dosage once every ten days.Patients were changed to monotherapy of sulfasalzine seventeen weeks later.The whole treatment lasted for 24 weeks.All participants were followed up at week 0,6,12,18,24 respectively and were evaluated by BASDAI 50.The primary end-point of this study was the percentage of patients achieved BASDAI 50 remission.Data were analyzed with SPSS version 17.0.Independent t-test and x2 test were adopted to analyze data.Results 90% of patients treated with combination therapy reached BASDAI50 at the 6th week.All patients in the G1 group achieved BASDAI 50 remission at 12th week,but the percentage dropped to 68.7% at 18th week,which gradually decreased to 37.5% at the 24th week.In G2 group,93.9% patients reached BASDAI50,which declined to 81.8% at the 18th week.The whole number accounted for 60% at the end point of 24th week.In G3 group,85.7% patients achieved BASDAI50 at the 12th week,accounted for 74.3% at 18th week,and declined to 68.6% at the 24th week.G3 group of patients presented a significantly higher rate than other groups(P<0.05).Conclusion Sulfasalzine and rhTNFR combination therapy can gain remission in active AS patients after treated for six weeks.Doctors may extend TNF antagonist treatment in order to achieve long-term remission.

Chinese Journal of Medical Instrumentation ; (6): 58-63, 2011.
Article in Chinese | WPRIM | ID: wpr-330520


It is significant to research the heart modeling for the diagnosis and treatment of heart disease. With the development of biomedical technology, material and computer science, there are new requirements for heart modeling and simulation in terms of heart data acquisition, modeling approach, clinical application and so on. The research status of heart geometric/anatomical model, heart electrophysiological model and mechanical dynamic model has been summarized in this paper, and the problems and trends of heart modeling have been analyzed synthetically.

Heart , Models, Biological , Research Design
Chinese Journal of Rheumatology ; (12): 785-788, 2011.
Article in Chinese | WPRIM | ID: wpr-423089


ObjectiveTo evaluate the adverse events occurred during tumour necrosis factor (TNF)-αblocker treatment in Chinese Han population patients with ankylosing spondylitis (AS).MethodsThis study had enrolled 369 Chinese Han population patients with ankylosing spondylitis.They all received TNF-αblocker treatment in the hospital.All 1011 administration were recorded in total.All of them were evaluated for adverse events 2 hours after injection,126 of them had received long-term TNF-α blocker injection,and they were followed-up at week 8,12,52,104.Mild immediate adverse events and long-term adverse events were all counted.SPSS 10.0 software package was used for Fisher's exact test.ResultsThree hundred and sixty-nine patients had 1011 administrations in total,652 had received rhTNFR:Fc,316 had infliximab,21had etanercept,22 had adalimumab injections.Adverse events 2 hours after injection were:17 (2.6%) for rhTNFR:Fc,12 (3.8%) for infliximab,0 for etanercept,1 (4.5%) for adalimumab.Twenty adverse events were mild(12 for rhTNFR:Fc,9 for infliximab),5 events were moderate(3 for rhTNFR:Fc,1 for infliximab,1 for adalimumab),4 events were severe(2 for rhTNFR:Fc,2 for infliximab).The frequency of adverse events were comparable between rhTNFR:Fc and Infliximab injection in immediate adverse reactions (P=0.31).One hundred and twenty-six (69 rhTNFR:Fc,57 infliximab) patients had long-term usage,and were followed-up at week 8,12,52,104,39 patients had adverse reactions:20 (51.3%) for rhTNFR:Fc,19(48.7%) for infliximab.Thirty-seven patients had infectious events(94.9% ),1 neurological event(2.6%),and 1 patient had tuberculosis relapse (2.6%).Outcomes were comparable with rhTNFR:Fc and infliximab in long-term usage(P=0.69).ConclusionAttention should be paid to the above events in Chinese Han patients with ankylosing spondylitis who were treated with TNF-α blocker treatment.Special attention should be paid to those patients who are in their third or fourth injection.The occurrence of immediate reaction or long-term adverse events between rhTNFR:Fc and infliximab are comparable.